Tang Feng, Liang Yuemian, Zhang Licai, Qiu Liquan, Xu Chengcheng
Department of Respiratory and Critical Care, Shanghai Pulmonary Hospital, Shanghai, 200433, China.
Department of Pathology, Affiliated Hospital of Hebei University, Baoding, 071000, China.
J Cardiothorac Surg. 2025 Jan 6;20(1):24. doi: 10.1186/s13019-024-03235-3.
Thoracotomy is a common treatment for non-small cell lung cancer (NSCLC). However, the significant trauma from this procedure can limit patients' postoperative prognosis. Therefore, it's crucial to find an easily detected indicator that can predict the prognosis of NSCLC patients undergoing thoracotomy. FAM83A-AS1 was hypothesized as a predictor for the therapeutic effectiveness of thoracotomy. We evaluated its correlation with patient outcomes and its significance in predicting postoperative prognosis, with the aim of providing a reference to improve postoperative prognosis of thoracotomy.
The study enrolled patients with NSCLC who underwent thoracotomy, and tissue samples were collected during surgery. Blood samples were collected preoperatively and three days postoperatively. PCR was used to analyze plasma FAM83A-AS1 levels. The significance of these levels in the patients' postoperative prognosis was evaluated via logistic regression and ROC analyses, with a follow-up period of six months.
FAM83A-AS1 was significantly upregulated in NSCLC and correlated with severe progression in patients. Thoracotomy suppressed FAM83A-AS1 expression and reduced CA50, CEA, and CYFRA21-1 levels. Postoperative plasma levels of FAM83A-AS1 positively correlated with CA50, CEA, and CYFRA21-1. Patients with worse prognoses had higher plasma FAM83A-AS1 levels. FAM83A-AS1 was identified as a risk factor for poor postoperative outcomes in NSCLC patients undergoing thoracotomy and could be used to identify patients at risk of worse prognosis.
An increase in FAM83A-AS1 in NSCL indicates severe disease development and can serve as a biomarker associated with thoracotomy, predicting a poor prognosis. It provides a potential indicator for patient outcomes.
开胸手术是治疗非小细胞肺癌（NSCLC）的常用方法。然而，该手术带来的巨大创伤会限制患者的术后预后。因此，找到一个易于检测的指标来预测接受开胸手术的NSCLC患者的预后至关重要。FAM83A-AS1被假设为开胸手术治疗效果的预测指标。我们评估了其与患者预后的相关性及其在预测术后预后中的意义，旨在为改善开胸手术的术后预后提供参考。
本研究纳入了接受开胸手术的NSCLC患者，并在手术期间采集了组织样本。术前和术后三天采集血样。采用聚合酶链反应（PCR）分析血浆FAM83A-AS1水平。通过逻辑回归和ROC分析评估这些水平在患者术后预后中的意义，随访期为六个月。
FAM83A-AS1在NSCLC中显著上调，且与患者的严重病情进展相关。开胸手术抑制了FAM83A-AS1的表达，并降低了CA50、癌胚抗原（CEA）和细胞角蛋白19片段（CYFRA21-1）水平。术后血浆FAM83A-AS1水平与CA50、CEA和CYFRA21-1呈正相关。预后较差的患者血浆FAM83A-AS1水平较高。FAM83A-AS1被确定为接受开胸手术的NSCLC患者术后不良结局的危险因素，可用于识别预后较差风险的患者。
NSCLC中FAM83A-AS1的升高表明疾病进展严重，可作为与开胸手术相关的生物标志物，预测预后不良。它为患者预后提供了一个潜在指标。
